All In Biotech

Drug Trial Radar · NCT04692181

SYN-004 Safety and Tolerability in Allo-HCT Subjects

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Feb 15, 2021

Primary completion

Sep 30, 2029

Study completion Sep 30, 2030

Sponsor

Lead sponsor
Theriva Biologics, Inc.Industry
Sponsor type
Industry
Collaborators
Washington University School of Medicine
First posted
Dec 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Objectives: 1. To evaluate the safety and tolerability of oral SYN-004 in adult allogeneic HCT (allo-HCT) recipients who develop fever after conditioning therapy and are treated with IV β-lactam antibiotics meropenem (MER), piperacillin tazobactam (PIP/TAZO), or cefepime (FEP). 2. To evaluate potential absorption of oral SYN-004 into the systemic circulation of allo-HCT recipients and potential SYN-004-mediated alterations to systemic levels and efficacy of IV MER, PIP/TAZO or FEP. 3. To evaluate potential protective effects of SYN-004 on the intestinal microbiome of allo-HCT recipients treated with IV MER, PIP/TAZO or FEP. 4. To obtain preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allo-HCT recipients treated with IV MER, PIP/TAZO or FEP

Conditions

  • Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
  • Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics

Interventions

  • SYN-004, Ribaxamase or PlaceboBiological

    SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SYN-004 systemic absorptionTime frame: No more than 28 days
  2. Systemic antibiotic concentrationsTime frame: Up to 8 hours after IV administration of antibiotic
  3. BacteremiaTime frame: Daily during treatment, and weekly until 30 days after discontinuation of SYN-004 or Placebo
  4. Bacterial intestinal infectionsTime frame: Daily during treatment, and weekly until 30 days after discontinuation of SYN-004 or Placebo
  5. Grade 3 or 4 adverse eventsTime frame: Up to 30 days after the last dose of SYN-004 or Placebo
  6. Overall survivalTime frame: Up to 30 days after the last dose of SYN-004 or Placebo

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.